Sandoz Files for Generic Tirzepatide: FDA Accepts First ANDA Applications
TL;DR: FDA accepted Sandoz's ANDAs for generic tirzepatide (29 Jun 2026) — first filing, but patents likely delay launch past 2027.
What Did the FDA Accept on 29 June 2026?
On 29 June 2026, the FDA accepted two Abbreviated New Drug Applications (ANDAs) filed by Sandoz, the Swiss generics and biosimilars group spun out of Novartis, for a generic tirzepatide autoinjector. The filings reference Eli Lilly's Mounjaro (tirzepatide, approved for type 2 diabetes) and Zepbound (tirzepatide, approved for chronic weight management) as the branded comparator products.[1]
Sandoz says the generic candidate was developed entirely in-house rather than licensed or partnered, and has described it as a filing that positions the company to potentially launch "one of the first generic tirzepatide products" available in the United States, should approval and patent clearance eventually align.[2] Trade coverage from Drug Store News, PharmaTutor, and the generics-industry publication Citeline all corroborated the filing and its 29 June acceptance date.[3]
Acceptance is not approval. An ANDA "acceptance" means the FDA's filing review found the application complete enough to enter substantive scientific review. It carries no timeline for approval and no launch date — see the next section for why the distinction matters here in particular.
What Is an ANDA, and Why Doesn't "Accepted" Mean "Approved"?
An Abbreviated New Drug Application is the standard US regulatory pathway for a generic manufacturer to seek approval to market a copy of an already-approved "reference listed drug" — here, Lilly's tirzepatide products. Unlike a full New Drug Application (NDA), an ANDA does not require the applicant to repeat the original clinical efficacy and safety trials; instead, the generic maker must demonstrate bioequivalence to the reference product and address any patents or exclusivity periods still in force.
"FDA accepts an ANDA for review" is a procedural checkpoint, not a scientific verdict. It confirms Sandoz's paperwork and manufacturing data met the threshold for the agency to begin its substantive review. From this point, three separate clocks matter: (1) how long the FDA's scientific review of bioequivalence data takes, which is not published in advance; (2) whether Lilly initiates patent-infringement litigation, which under Hatch-Waxman rules can trigger an automatic stay of approval; and (3) whether the underlying exclusivity and patent protections have expired by the time review concludes.
When Could Generic Tirzepatide Actually Reach the Market?
The FDA approved Mounjaro (tirzepatide) on 13 May 2022. Under Hatch-Waxman rules, a genuinely new active ingredient receives five years of New Chemical Entity (NCE) exclusivity, during which the FDA cannot approve any ANDA referencing it. That exclusivity is due to expire in May 2027 — the earliest point at which an ANDA for generic tirzepatide could legally be approved, regardless of how quickly Sandoz's filing otherwise clears review.[4]
| Milestone | Date / status |
|---|---|
| Mounjaro FDA approval (NCE clock starts) | 13 May 2022 |
| Sandoz ANDA filing accepted for review | 29 June 2026 |
| NCE exclusivity expires (earliest possible ANDA approval) | May 2027 |
| Device / formulation / method-of-use patents | Tracked by generic-industry analysts as extending into the mid-2030s |
NCE exclusivity is a regulatory clock, not a patent clock, and the two are frequently confused in casual coverage of "generic launch dates." Lilly holds a separate portfolio of patents covering the tirzepatide molecule, its autoinjector device, and specific formulations, which patent-tracking services report as extending well beyond 2027 — into the mid-2030s on current listings.[5] Unless those patents are invalidated, licensed, or settled through litigation, an ANDA can be "approved" in a regulatory sense while still being legally blocked from launching. In practice, that means Sandoz's 29 June filing marks the start of a process that is more likely to run into the next decade than to deliver a generic tirzepatide product on pharmacy shelves in 2027.
How Does This Differ From Compounded or Research-Grade Tirzepatide?
The Sandoz filing is easy to conflate with two other tirzepatide-adjacent supply routes that have made regulatory news in 2026, but all three are governed by entirely separate FDA frameworks:
1. ANDA generics (this article)
A licensed generic drug manufacturer seeking FDA approval to sell a bioequivalent copy of a branded, already-approved medicine. Governed by the Hatch-Waxman Act. This is what Sandoz filed on 29 June 2026.
2. 503B compounding pharmacies
Outsourcing facilities that may prepare patient-specific or office-stock versions of a drug under separate FDA rules, typically when a branded product is in shortage. Tirzepatide's compounding eligibility is governed by its own bulks-list determinations, distinct from the ANDA process described here.
3. Research-use reagents (what Velox Peptides supplies)
Tirzepatide manufactured and HPLC-verified strictly as an in vitro laboratory reagent for qualified researchers. It is not a medicine, is not evaluated by the FDA or MHRA as a drug product, and has no regulatory relationship to Sandoz's ANDA, to Lilly's branded products, or to any compounding pathway.
None of the three pathways confers any regulatory status on the others. A future ANDA approval for generic tirzepatide would only ever apply to a licensed pharmaceutical product dispensed by prescription — it would have no bearing on how research reagents referencing the same peptide sequence are manufactured, tested, or supplied for laboratory use.
What Should UK Researchers Take From This?
The ANDA process is a US-specific mechanism under the Federal Food, Drug, and Cosmetic Act; it has no legal force in the UK and does not touch the Human Medicines Regulations 2012 or MHRA guidance that governs research-reagent supply in Great Britain and Northern Ireland. Even once (or if) a US generic tirzepatide product is eventually approved, it would remain a separate US-licensed medicine, unrelated to any UK-supplied research chemical bearing the same compound name.
For researchers tracking the tirzepatide literature, the practical takeaway is narrower than the headline: a generic-filing acceptance is a commercial and patent-law milestone, not a new efficacy or safety data point. It changes nothing about tirzepatide's published pharmacology, and it should not be read as signalling any near-term change to how the compound is accessed for research purposes.
Tirzepatide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Sandoz. US FDA accepts Sandoz applications for proposed in-house development of generic tirzepatide GLP-1s. Press release, 29 June 2026. sandoz.com
- Drug Store News. FDA accepts Sandoz applications for proposed generic tirzepatide GLP-1s. 2026. drugstorenews.com
- Citeline Generics Bulletin. Sandoz starts generic tirzepatide race with FDA filing acceptance. 2026. insights.citeline.com; corroborated by PharmaTutor, pharmatutor.org
- Drugs.com. Mounjaro (tirzepatide) FDA Approval History. Approval date 13 May 2022. drugs.com
- DrugPatentWatch. Mounjaro patent and exclusivity tracking. drugpatentwatch.com
Frequently Asked Questions
What did the FDA accept from Sandoz on 29 June 2026?
The FDA accepted two Abbreviated New Drug Applications (ANDAs) filed by Sandoz for an in-house-developed generic tirzepatide autoinjector, referencing Eli Lilly's Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Acceptance means the filings passed an initial completeness check and enter FDA scientific review — it is not an approval and carries no launch date.
Is generic tirzepatide available now?
No. No generic tirzepatide product is FDA-approved or on the market. Sandoz's ANDA filings are the opening step of a multi-year review and litigation process, and reference-listed-drug patent protection is generally understood to extend well beyond tirzepatide's 2027 exclusivity expiry.
When does tirzepatide's patent protection expire?
Tirzepatide's five-year New Chemical Entity (NCE) exclusivity, which began when the FDA approved Mounjaro on 13 May 2022, expires in May 2027 — the earliest point an ANDA could be approved. Separate device, formulation and method-of-use patents held by Eli Lilly are tracked by generic-industry analysts as extending into the mid-2030s, which is why a 2027 exclusivity expiry does not imply a 2027 generic launch.
Does an ANDA filing affect research-grade tirzepatide supply?
No. An ANDA is a pathway for a licensed generic medicine to reach pharmacies once approved; it has no bearing on tirzepatide sold as an in vitro research reagent. Velox Peptides' tirzepatide reference material is manufactured and HPLC-verified as a research chemical, not a pharmaceutical product, and is entirely separate from the Sandoz filing, from Lilly's branded products, and from the FDA's separate review of tirzepatide's 503B compounding status.
How is this different from the FDA peptide-compounding reviews covered elsewhere on this site?
Different pathway entirely. The PCAC hearings covered in our other 2026 regulatory guides concern whether US compounding pharmacies may prepare peptides such as BPC-157 and TB-500 under Section 503A. The Sandoz filing concerns Abbreviated New Drug Applications — the standard route by which a licensed generic drug manufacturer seeks approval to sell a copy of an already-approved medicine. The two frameworks do not overlap.